Replies to post #41666 on Biotech Values

[iwfal]

alxn in trial had a p value of .08. it was the subset that had a p-value of .03

Not per your own cite (which is the the one I provided on the MCU board - medscape version of paper). As I said, the 30 day Death/MI ITT p value is given as 0.03 (in Figure 4). Yes, the CABG subset was worse p value, but ITT should always be a more important number. (And note that the clinical efficacy was virtually identical at 30 days regardless of subgroup)

As I have mentioned before, they, like MCU, also had good results in another ph ii. Yet they wiffed in ph iii. Again, the point is that it is a very very good bet that there are valuable lessons to be learned out of the Alexion trials.